Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
pharma · Multiple Myeloma · Relapsed/Refractory Multiple Myeloma
Janssen-Cilag International N.V
Janssen-Cilag International N.V.
Janssen-Cilag International N.V drug portfolio — 159 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
São Paulo, EU HQ
13 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- São Paulo, EU
- Employees
- 13
- Programs
- 161
- Drugs
- 159
- Patents
- 0
Janssen-Cilag International N.V pipeline
Portfolio lens on 159 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Janssen-Cilag International N.V drug portfolio — 159 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
abiraterone
Antineoplastic and immunomodulating agents (L02)Antineoplastic and immunomodulating agents (L02) compound in Janssen-Cilag International N.V's portfolio. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Steroid 5-alpha-reductase inhibitor
-
abiraterone acetate
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Steroid 17-alpha-hydroxylase/17,20 lyase.
- Target
- Steroid 17-alpha-hydroxylase/17,20 lyase
- Mechanism
- Cytochrome P450 17A1 inhibitor
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
amivantamab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Janssen-Cilag International N.V's portfolio. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor inhibitor
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
apalutamide
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
azacitidine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 3A inhibitor
-
azathioprine
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Amidophosphoribosyltransferase.
- Target
- Amidophosphoribosyltransferase
- Mechanism
- Amidophosphoribosyltransferase inhibitor
-
US regulatory status: approved. Molecular target: Amidophosphoribosyltransferase.
- Target
- Amidophosphoribosyltransferase
- Mechanism
- Amidophosphoribosyltransferase inhibitor
-
bedaquiline
Antiinfectives for systemic use (J04)Antiinfectives for systemic use (J04) compound in Janssen-Cilag International N.V's portfolio.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
bortezomib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteosome inhibitor
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
US regulatory status: approved.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
carfilzomib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteosome inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
cetuximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cell membrane.
- Target
- Cell membrane
- Mechanism
- Cell membrane inhibitor
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
ciltacabtagene autoleucel
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Janssen-Cilag International N.V's portfolio. Molecular target: Tumor necrosis factor receptor superfamily member 17.
- Target
- Tumor necrosis factor receptor superfamily member 17
- Mechanism
- Tumor necrosis factor receptor superfamily member 17 binding agent
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
cytarabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
daratumumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.
- Target
- ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
- Mechanism
- Lymphocyte differentiation antigen CD38 inhibitor
-
degarelix
Antineoplastic and immunomodulating agents (L02)Antineoplastic and immunomodulating agents (L02) compound in Janssen-Cilag International N.V's portfolio. Mechanism: Gonadotropin-releasing hormone receptor antagonist.
- Mechanism
- Gonadotropin-releasing hormone receptor antagonist
-
deucravacitinib
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Non-receptor tyrosine-protein kinase TYK2.
- Target
- Non-receptor tyrosine-protein kinase TYK2
- Mechanism
- Tyrosine-protein kinase TYK2 negative allosteric modulator
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
dolutegravir
Antiinfectives for systemic use (J05)US regulatory status: approved.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
dupilumab
Dermatologicals (D11)US regulatory status: approved. Molecular target: Interleukin-4 receptor subunit alpha.
- Target
- Interleukin-4 receptor subunit alpha
- Mechanism
- Interleukin-4 receptor subunit alpha antagonist
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records. Molecular target: IgG receptor FcRn large subunit p51.
- Target
- IgG receptor FcRn large subunit p51
- Mechanism
- IgG receptor FcRn large subunit p51 antagonist
-
efgartigimod alfa
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: IgG receptor FcRn large subunit p51.
- Target
- IgG receptor FcRn large subunit p51
- Mechanism
- IgG receptor FcRn large subunit p51 antagonist
-
elotuzumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: SLAM family member 7.
- Target
- SLAM family member 7
- Mechanism
- SLAM family member 7 inhibitor
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
entecavir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA polymerase/reverse transcriptase.
- Target
- DNA polymerase/reverse transcriptase
- Mechanism
- DNA polymerase/reverse transcriptase inhibitor
-
erdafitinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Fibroblast growth factor receptor.
- Target
- Fibroblast growth factor receptor
- Mechanism
- Fibroblast growth factor receptor inhibitor
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
esketamine
Nervous system (N06)Nervous system (N06) compound in Janssen-Cilag International N.V's portfolio. Molecular target: Glutamate [NMDA] receptor.
- Target
- Glutamate [NMDA] receptor
- Mechanism
- Glutamate [NMDA] receptor negative allosteric modulator
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
etanercept
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA polymerase (alpha/delta/epsilon).
- Target
- DNA polymerase (alpha/delta/epsilon)
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
golimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
guselkumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-23.
- Target
- Interleukin-23
- Mechanism
- Interleukin-23 inhibitor
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
human normal immunoglobulin
Antiinfectives for systemic use (J06)Antiinfectives for systemic use (J06) compound in Janssen-Cilag International N.V's portfolio. Mechanism: Replacement therapy, immunomodulatory effects.
- Mechanism
- Replacement therapy, immunomodulatory effects
-
human normal immunoglobulin (ivig)
Antiinfectives for systemic use (J06)Antiinfectives for systemic use (J06) compound in Janssen-Cilag International N.V's portfolio. Mechanism: Replacement therapy, immunomodulatory effects.
- Mechanism
- Replacement therapy, immunomodulatory effects
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
ibrutinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
-
US regulatory status: approved.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records. Mechanism: DNA topoisomerase I inhibitor.
- Mechanism
- DNA topoisomerase I inhibitor
-
lazertinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Janssen-Cilag International N.V's portfolio. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
lenalidomide
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.
- Target
- CRL4(CRBN) E3 ubiquitin ligase
- Mechanism
- CRL4(CRBN) E3 ubiquitin ligase inhibitor
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
mercaptopurine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Amidophosphoribosyltransferase.
- Target
- Amidophosphoribosyltransferase
- Mechanism
- Amidophosphoribosyltransferase inhibitor
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records. Mechanism: Mitochondrial complex I (NADH dehydrogenase) inhibitor.
- Mechanism
- Mitochondrial complex I (NADH dehydrogenase) inhibitor
-
methotrexate
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Dihydrofolate reductase inhibitor
-
midazolam
Nervous system (N05)US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records. Mechanism: Cysteinyl leukotriene receptor 1 antagonist.
- Mechanism
- Cysteinyl leukotriene receptor 1 antagonist
-
US regulatory status: approved. Molecular target: Cysteinyl leukotriene receptor 1.
- Target
- Cysteinyl leukotriene receptor 1
- Mechanism
- Cysteinyl leukotriene receptor 1 antagonist
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Various (V04) compound in Janssen-Cilag International N.V's portfolio.
-
nipocalimab
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in Janssen-Cilag International N.V's portfolio. Molecular target: IgG receptor FcRn large subunit p51.
- Target
- IgG receptor FcRn large subunit p51
- Mechanism
- IgG receptor FcRn large subunit p51 antagonist
-
niraparib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Janssen-Cilag International N.V's portfolio. Molecular target: Poly [ADP-ribose] polymerase 2.
- Target
- Poly [ADP-ribose] polymerase 2
- Mechanism
- Poly [ADP-ribose] polymerase-1 inhibitor
-
US regulatory status: approved. Molecular target: Poly [ADP-ribose] polymerase 2.
- Target
- Poly [ADP-ribose] polymerase 2
- Mechanism
- Poly [ADP-ribose] polymerase 2 inhibitor
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Potassium-transporting ATPase.
- Target
- Potassium-transporting ATPase
- Mechanism
- Potassium-transporting ATPase inhibitor
-
orlistat
Alimentary tract and metabolism (A08)US regulatory status: approved. Molecular target: Gastric triacylglycerol lipase.
- Target
- Gastric triacylglycerol lipase
- Mechanism
- Pancreatic lipase inhibitor
-
osimertinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Janssen-Cilag International N.V's portfolio. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
pomalidomide
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.
- Target
- CRL4(CRBN) E3 ubiquitin ligase
- Mechanism
- CRL4(CRBN) E3 ubiquitin ligase inhibitor
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
pregabalin
Nervous system (N02)US regulatory status: approved. Molecular target: Voltage-gated calcium channel.
- Target
- Voltage-gated calcium channel
- Mechanism
- Voltage-gated calcium channel modulator
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records. Mechanism: Potassium-transporting ATPase inhibitor.
- Mechanism
- Potassium-transporting ATPase inhibitor
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
relugolix
Systemic hormonal preparations (H01)US regulatory status: approved. Molecular target: Gonadotropin-releasing hormone receptor.
- Target
- Gonadotropin-releasing hormone receptor
- Mechanism
- Gonadotropin-releasing hormone receptor antagonist
-
US regulatory status: approved. Molecular target: Tyrosine-protein kinase JAK1.
- Target
- Tyrosine-protein kinase JAK1
- Mechanism
- Tyrosine-protein kinase JAK2 inhibitor
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
sitaxentan sodium
Cardiovascular system (C02)Cardiovascular system (C02) compound in Janssen-Cilag International N.V's portfolio. Molecular target: Endothelin receptor, ET-A/ET-B.
- Target
- Endothelin receptor, ET-A/ET-B
- Mechanism
- Endothelin receptor, ET-A/ET-B antagonist
-
US regulatory status: approved.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
tacrolimus
Dermatologicals (D11)US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.
- Target
- Peptidyl-prolyl cis-trans isomerase FKBP1A
- Mechanism
- FK506-binding protein 1A inhibitor
-
talquetamab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Janssen-Cilag International N.V's portfolio. Molecular target: G-protein coupled receptor family C group 5 member D.
- Target
- G-protein coupled receptor family C group 5 member D
- Mechanism
- T cell surface glycoprotein CD3 binding agent
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
teclistamab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Janssen-Cilag International N.V's portfolio. Molecular target: T cell surface glycoprotein CD3.
- Target
- T cell surface glycoprotein CD3
- Mechanism
- Tumor necrosis factor receptor superfamily member 17 binding agent
-
US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
-
tenofovir disoproxil
Antiinfectives for systemic use (J05)Antiinfectives for systemic use (J05) compound in Janssen-Cilag International N.V's portfolio.
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Beta-1 adrenergic receptor.
- Target
- Beta-1 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor antagonist
-
tocilizumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-6 receptor subunit alpha.
- Target
- Interleukin-6 receptor subunit alpha
- Mechanism
- Interleukin-6 receptor alpha subunit inhibitor
-
US regulatory status: approved. Molecular target: Interleukin-6 receptor subunit alpha.
- Target
- Interleukin-6 receptor subunit alpha
- Mechanism
- Interleukin-6 receptor alpha subunit inhibitor
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
ustekinumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-12.
- Target
- Interleukin-12
- Mechanism
- Interleukin-23 inhibitor
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Peptidoglycan.
- Target
- Peptidoglycan
- Mechanism
- Peptidoglycan inhibitor
-
venetoclax
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Apoptosis regulator Bcl-2.
- Target
- Apoptosis regulator Bcl-2
- Mechanism
- Apoptosis regulator Bcl-2 inhibitor
-
vinflunine
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Janssen-Cilag International N.V's portfolio. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to Janssen-Cilag International N.V in public FDA and regional records. Molecular target: Prothrombin.
- Target
- Prothrombin
- Mechanism
- Thrombin inhibitor